15 December 2022 
EMA/CHMP/931343/2022 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Hemlibra 
emicizumab 
On 15 December 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Hemlibra. The marketing authorisation holder for this medicinal product is Roche Registration GmbH. 
The CHMP adopted an extension to an existing indication to include routine prophylaxis of bleeding 
episodes in patients with haemophilia A without factor VIII inhibitors who have moderate disease with  
severe bleeding phenotype. For information, the full indications for Hemlibra will be as follows:2  
Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A 
(congenital factor VIII deficiency): 
• 
• 
with factor VIII inhibitors 
without factor VIII inhibitors who have: 
severe disease (FVIII < 1%) 
o 
o  moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding 
phenotype. 
Hemlibra can be used in all age groups. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
